Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
"I wasn’t expecting these results among women in this lower age group, because we usually see increased risk for heart disease among older women," one cardiologist said. "It was definitely surprising.”
While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things.
The portable device uses HeartBeam's patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthetic 12-lead ECG.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
